TRIVALENT, BISPECIFIC ANTIBODIES
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
3 Citations
26 Claims
-
1-17. -17. (canceled)
-
18. :
- A method for treating a human suffering from cancer by administering an effective amount of trivalent, bispecific antibody to a human in need of such treatment, wherein the trivalent, bispecific antibody comprises
a) a full length antibody that specifically binds to a first antigen wherein the full length antibody consists of two antibody heavy chains and two antibody light chains; b) a polypeptide consisting of ba) an antibody heavy chain variable domain (VH), or bb) an antibody heavy chain variable domain (VH) and an antibody constant domain 1 (CH1), wherein the N-terminus of the VH domain of the polypeptide is fused via a peptide connector to the C-terminus of one of the two heavy chains of the full length antibody; c) a polypeptide consisting of ca) an antibody light chain variable domain (VL), or cb) an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL); wherein N-terminus of the VL domain of the polypeptide is fused via a peptide connector to the C-terminus of the other of the two heavy chains of the full length antibody; and wherein the antibody heavy chain variable domain (VH) of the polypeptide under b) and the antibody light chain variable domain (VL) of the polypeptide under c) together form an antigen-binding site specifically binding to a second antigen. - View Dependent Claims (19, 20, 21, 22, 23, 24, 25, 26)
an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the interface of the second CH3 domain within which a protuberance within the interface of the first CH3 domain is positionable.
- A method for treating a human suffering from cancer by administering an effective amount of trivalent, bispecific antibody to a human in need of such treatment, wherein the trivalent, bispecific antibody comprises
-
20. :
- The method of claim 19, wherein
in i) the amino acid residue having a larger side chain volume is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), tryptophan (W); and in ii) the amino acid residue having a smaller side chain volume is selected from the group consisting of alanine (A), serine (S), threonine (T), valine (V).
- The method of claim 19, wherein
-
21. :
- The method of claim 20, wherein both CH3 domains are further altered by the introduction of cysteine as an amino acid in each CH3 domain such that a disulfide bridge between both CH3 domains can be formed.
-
22. :
- The method of claim 19, wherein
the CH3 domain under i) comprises a T366W mutation; and the CH3 domain under ii) comprises T366S, L368A, and Y407V mutations.
- The method of claim 19, wherein
-
23. :
- The method of claim 19, wherein
the CH3 domain under i) comprises Y349C and T366W mutations; and the CH3 domain under ii) comprises S354C, T366S, L368A, and Y407V mutations.
- The method of claim 19, wherein
-
24. :
- The method of claim 18, wherein
the antibody heavy chain variable domain (VH) of the polypeptide under b) and the antibody light chain variable domain (VL) of the polypeptide under c) are linked and stabilized via a interchain disulfide bridge by introduction of a disulfide bond between the following positions; i) heavy chain variable domain position 44 to light chain variable domain position 100, ii) heavy chain variable domain position 105 to light chain variable domain position 43, or iii) heavy chain variable domain position 101 to light chain variable domain position 100.
- The method of claim 18, wherein
-
25. :
- The method of claim 18, wherein
the antibody heavy chain variable domain (VH) of the polypeptide under b) and the antibody light chain variable domain (VL) of the polypeptide under c) are linked and stabilized via a interchain disulfide bridge by introduction of a disulfide bond between the following positions;
i) heavy chain variable domain position 44 to light chain variable domain position 100.
- The method of claim 18, wherein
-
26. :
- The method of claim 18, wherein the peptide connectors under b) and c) are identical peptides with a length between 25 and 50 amino acids.
Specification